The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC)
To evaluate the efficacy of TAI combine toripalimab in advanced HCC.
Hepatocellular Carcinoma
COMBINATION_PRODUCT: Transarterial Chemoinfusion (TAI) Combine Toripalimab
PFS, progression-free survival, From date of randomization until the date of progression, assessed up to 36 months|ORR, objective response rate, From date of randomization until the date of death, assessed up to 36 months
OS, overall survival, From date of randomization until the date of death from any cause, assessed up to 36 months|DCR, disease control rate, From date of randomization until the date of death, assessed up to 36 months
To evaluate the efficacy of TAI combine toripalimab in advanced HCC.